The Novavax Analyst: Vernon Bernardino reiterated a top pick Buy rating on Novavax and raised the price target from $50 to $101.
The Novavax Thesis: Novavax’s COVID-19 vaccine candidate NVX-CoV2373 is likely a sustainable long-term market opportunity, Bernardino said in a Monday note. (See his track record 여기클릭.)
H.C. Wainwright held a virtual fireside chat with Novavax executives Thursday.
The $388 million in CEPI funding for Novavax de-risks clinical development of the vaccine candidate, the analyst said.
Novavax is capable of being a robust competitor against larger vaccine makers, likely helping it realize over $400 million in annual sales of NVX-CoV2373, he said.
Discussions with former U.S. Health and Human Services and BARDA official Kevin Gilligan increased Bernardino’s positive view on Novavax’s prospects for realizing a near-term lucrative market opportunity as well as sustained commercial opportunity, the analyst said.
“Gilligan concluded that multiple therapeutic approaches, including antiviral and antibiotic strategies, would be important for a near-term response to the pandemic.”
Gilligan said it’s likely that booster vaccinations, new vaccines against mutated SARS-CoV-2 and antiviral and antibody therapies will be needed to prepare for future pandemics, the analyst said.
Matrix-M and vaccine adjuvants in general are underappreciated, Gilligan told H.C. Wainwright.
“In a situation where a significant percentage of the world’s 7B+ population may need to be vaccinated, the potential of adjuvants to boost vaccine efficacy, and thus, be dose-sparing could be important if not enough CoV vaccine is available for global distribution.”
At last check, Novavax shares were adding 8.3% to $83.81.
관련 링크 :
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Novavax Beefs Up Executive Team As It Sprints In The Coronavirus Vaccine Race
NVAX에 대한 최신 등급
|6월 2020||라일리 FBR||유지하다||사다|
|6월 2020||HC Wainwright & Co.||유지하다||사다|
|6월 2020||캔터 피츠 제럴드||유지하다||초과 중량|
NVAX에 대한 더 많은 분석가 평가보기
최신 분석가 등급보기
벤 징가 (Benzinga)에서 더보기
© 2020 Benzinga.com. Benzinga는 투자 조언을 제공하지 않습니다. 판권 소유.